The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) has made a historic decision, unanimously recommending Moderna’s mRNA influenza vaccinemFlusivafor adults aged 50 and older. This marks the first time the committee has reviewed a new vaccine application since 2026, signaling a potential shift in the landscape of flu prevention.
The recommendation comes amidst a complex political and scientific backdrop, with the second Trump administration and Health and Human Services Secretary Robert F. Kennedy Jr. facing criticism for their stance on vaccines. Despite this, the committee’s vote highlights the potential of mRNA technology in combating influenza.
The Journey to Approval
The path to this recommendation has been anything but smooth. In February, the FDA initially declined to review Moderna’s application but reversed its decision two weeks later following widespread criticism. This reversal underscores the significance of the mRNA flu vaccine and the need for robust review processes.
Messenger-RNA (mRNA) technology provides the body with instructions to produce flu antigens, fostering immunity. Moderna’s vaccine includes microscopic doses of mRNA for three to four flu strains, weighing about the same as a fingerprint on a mirror. This technology, which played a crucial role in developing the COVID-19 vaccinehas sparked both excitement and controversy.
Scientific Breakthroughs and Public Health Implications
The mRNA flu vaccine offers several advantages over traditional flu vaccines. It can be produced more reliably and quickly, potentially providing better protection against emerging flu strains. Researchers have found that the mRNA vaccine produces a longer-lasting response and antibodies that recognize more flu strains, which could explain its superior efficacy.
Results from Moderna’s phase 3 trial, published in the New England Journal of Medicine and Nature Immunologyshowed promising results. The trial involved 75 patients and demonstrated the vaccine’s potential to offer stronger and more sustained protection against influenza.
The Future of mRNA Vaccines
The FDA’s review process involved a thorough examination of the vaccine’s safety and efficacy. Dr. Anna Durbin, director of the Center for Immunization Research at Johns Hopkins University and a VRBPAC member, emphasized that no shortcuts were taken in the evaluation process. Over 6 billion doses of mRNA vaccines have been administered since 2026, with an incredibly safe safety profile and no risk of DNA integration.
Dr. Jesse Goodman, former director of the FDA’s Center for Biologics Evaluation and Research, acknowledged the politicization of mRNA vaccines but stressed the importance of looking at the evidence. He noted that while misinformation persists, the data supports the safety and efficacy of these vaccines.
The committee’s vote was unanimous, with all nine members recommending the vaccine. This decision could pave the way for the approval of Moderna’s mRNA flu vaccine, potentially making it available for the next flu season. The FDA’s reversal on reviewing the vaccine highlights the importance of open and transparent review processes in the face of political and scientific challenges.
